Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.61 |
| ▸ | RELA | Q04206 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | EP300 | Q09472 | 1/20 | 0.53 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.53 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | NEK2 | P51955 | 1/20 | 0.50 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27623280 | 0.98 | MAPT (0.59) | MAPTSMN1; SMN2LMNAPOLBNFKB1 | |
| SCHEMBL5236125 | 0.89 | GAA (0.52) | MAPTSMN1; SMN2LMNAPOLBNFKB1 | |
| SCHEMBL27831942 | 0.84 | LMNA (0.49) | MAPTSMN1; SMN2LMNAPOLBNFKB1 | |
| SCHEMBL27812871 | 0.84 | LMNA (0.45) | MAPTSMN1; SMN2LMNAPOLBNFKB1 | |
| SCHEMBL4030721 | 0.83 | MAPT (0.59) | MAPTSMN1; SMN2LMNAPOLBNFKB1 | |
| SCHEMBL2027797 | 0.81 | GAA (0.56) | MAPTSMN1; SMN2LMNAPOLBNFKB1 | |
| SCHEMBL28798 | 0.81 | NR4A1 (0.65) | MAPTSMN1; SMN2TSHRALDH1A1NR4A1 | |
| SCHEMBL29406630 | 0.81 | NR4A1 (0.65) | MAPTSMN1; SMN2TSHRALDH1A1NR4A1 | |
| SCHEMBL30838413 | 0.81 | NR4A1 (0.65) | MAPTSMN1; SMN2TSHRALDH1A1NR4A1 | |
| SCHEMBL30838412 | 0.81 | NR4A1 (0.65) | MAPTSMN1; SMN2TSHRALDH1A1NR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102770182-B | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2014-10-29 | — | — | CN | claimed |
| US-20060223868-A1 | Heterocyclic amides exhibiting and inhibitory activity at the vanilloid receptor 1(vr1) | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | claimed |
| EP-1622884-A1 | NEW HETEROCYCLIC AMIDES EXHIBITING AN INHIBITORY ACTIVITY AT THE VANILLOID RECEPTOR 1 (VR1). | AstraZeneca AB (SE) | 2006-02-08 | — | — | EP | claimed |
| WO-2004096784-A1 | NEW HETEROCYCLIC AMIDES EXHIBITING AN INHIBITORY ACTIVITY AT THE VANILLOID RECEPTOR 1 (VR1). | ASTRAZENECA AB (SE) | 2004-11-11 | — | — | WO | claimed |
| CN-103923021-B | It is suitable for the heteroaryl compound of E1 activating enzyme inhibitors | 米伦纽姆医药公司 | 2018-03-30 | — | — | CN | disclosed |
| US-9718788-B2 | Heteroaryl compounds useful as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170050935-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
| US-9458108-B2 | Heteroaryl compounds useful as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9340522-B2 | Pyrazolone-derivatives and their use as PDE-4 inhibitors | TAKEDA GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-20160039761-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-11 | — | — | US | disclosed |
| US-9150525-B2 | Heteroaryl compounds useful as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150268246-A1 | LUMINESCENT COMPOUNDS | SETA BIOMEDICALS, LLC | 2015-09-24 | — | — | US | disclosed |
| US-20030013760-A1 | Substituted 1-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them | BRENDEL JOACHIM (DE) | 2003-01-16 | — | — | US | disclosed |
| EP-1242360-A2 | EXCIPLEXES | THE VICTORIA UNIVERSITY OF MANCHESTER (GB) | 2002-09-25 | — | — | EP | disclosed |
| WO-2002026696-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
| WO-2001046121-A2 | EXCIPLEXES | THE VICTORIA UNIVERSITY OF MANCHESTER (GB) | 2001-06-28 | — | — | WO | disclosed |
| EP-0810205-B1 | Substituted 1-naphtoylguanidines, process for their preparation, their use as medicament or diagnostic agent and medicaments containing them | HOECHST AG (DE) | 2001-03-28 | — | — | EP | disclosed |
| CN-1062859-C | Substd. 1-naphthoyl guanidines, their preparing method, use and drug contg. them | HOECHST AG (DE) | 2001-03-07 | — | — | CN | disclosed |
| CN-1167758-A | Substd. 1-naphthoyl guanidines, their preparing method, use and drug contg. them | HOECHST AG (DE) | 1997-12-17 | — | — | CN | disclosed |
| EP-0810205-A1 | Substituted 1-naphtoylguanidines, process for their preparation, their use as medicament or diagnostic agent and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223868-A1 | Heterocyclic amides exhibiting and inhibitory activity at the vanilloid receptor 1(vr1) | AVPR1A, AVPR2, TRPV1 | MAPT 4661/4885SMN1; SMN2 3834/4885LMNA 3819/4885 |
| US-20030013760-A1 | Substituted 1-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them | TNNI3, TNNT2, SCN1B | MAPT 4802/4885SMN1; SMN2 1212/4885LMNA 159/4885 |
| US-20170050935-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | RCE1, ECE1, UBE2E1 | MAPT 3076/4885SMN1; SMN2 753/4885LMNA 2893/4885 |
| US-20160039761-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | RCE1, ECE1, UBE2E1 | MAPT 3076/4885SMN1; SMN2 753/4885LMNA 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.